Inpatient costs of major cardiovascular events

American Journal of Cardiovascular Drugs

Volumn 1, Issue 3, 2001, Pages 205-217

  Radensky, Paul W ^a,c   Berliner, Elise ^b   Archer, Jennifer W ^a   Dournaux, Susan F ^a  

^a Health Law Department   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SURGERY; DIAGNOSIS RELATED GROUP; ECONOMICS; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; TREATMENT OUTCOME; UTILIZATION REVIEW;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SURGICAL PROCEDURES; DIAGNOSIS-RELATED GROUPS; HOSPITAL COSTS; HUMANS; INPATIENTS; LENGTH OF STAY; TREATMENT OUTCOME; UTILIZATION REVIEW;

EID: 2442418832     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/00129784-200101030-00006     Document Type: Article

References (40)

1. American Heart Association [online]. Available from URL: http://www.americanheart. org/HeartandStrokeAZGuide/cvds.html [Accessed 2000 May 26]
2. American Heart Association [online]. Available from URL: http://www.americanheart. org/statistics/10econom.html [Accessed 2000 May 26]
3. O?Connor CM, Radensky PW, Unger AN, et al. Hospital use and costs among patients with nonischemic cardiomyopathy in the first prospective randomized amlodipine survival evaluation study. Clin Ther 1999; 21: 1254-65
4. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93: 1796-802
5. Caro J, Klittich W, McGuire A, et al. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS: West of Scotland Coronary Prevention Study. Eur Heart J 1999; 20: 263-8
6. Weintraub WS, Culler SD, Kosinski A, et al. Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS [Treat Angina With Aggrastat (tirofiban) and determine cost of therapy with invasive or conservative strategy]- TIMI 18 trial. Am J Cardiol 1999; 83: 317-22
7. Bathina MN, Mickelsen S, Brooks C, et al. Radiofrequency catheter ablation versus medical therapy for initial treatment of supraventricular tachycardia and its impact on quality of life and healthcare costs. Am J Cardiol 1998; 82: 589-93
8. Murdock DK, Schumock GT, Kaliebe J, et al. Clinical and cost comparison of ibutilide and direct-current cardioversion for atrial fibrillation and flutter. Am J Cardiol 2000; 85: 503-6
9. .1997 Medicare Provider Analysis Review (MedPAR) [online]. Avaible from URL: http://www.hcfa.gov/stats/medpar/medpar.htm [Accessed 1999, Dec 31]
10. International classification of diseases, 9th rev., Clinical Modification. 5th ed, CDROM, 1999. American Medical Association, Medicode Inc.
11. Diagnosis related groups, definition manual. Version 16.0. 3M Health Information Systems
12. Diagnosis related groups, definition manual, Version 14.0. 3M Health Information Systems
13. Diagnosis related groups, definition manual, Version 15.0. 3M Health Information Systems
14. International classification of diseases, 9th rev., Clinical Modification. 5th ed, Vol 1, 2 and 3, 1998. American Medical Association, Medicode Inc.
15. International classification of diseases, 9th rev. Clinical Modification. 5th ed. Vol 1, 2 and 3, 1997. American Medical Association, Medicode Inc.
16. Healthcare Cost and Utilization Project, 1988-1996 (HCUP), Agency for Healthcare Quality and Research [date file]
17. US Federal Register, Vol. 63, No. 147, Jul 31, 1998, 40956
18. US Federal Register, Vol. 62, No. 168, Aug 29, 1997, 45974
19. US Federal Register, Vol. 63, No. 89, May 8, 1998, 25672
20. Health Care Financing Administration, Provider Specific File, PSPECS Final FY 1999 [online]. Available from URL: http://www.hcfa.gov/stats/pufiles. htm [Accessed 2000 May 15]
21. .1996 Medicare Provider Analysis Review (MedPAR) [online] Available from URL: http://www.hcfa.gov/stats/medpar/medpar.htm [Accessed 2000 May 15]
22. FY 1998 Medicare Payment Advisory Commission Prospective Payment System Hospital Input Price Index. Prospective Payment Assessment Commission. Table 1-1 Update Framework for PPS Hospital Operating Payments, FY 1998. Report and Recommendations to the Congress, March 1, 1997, 21. Prospective Payment Assessment Commission, Washington DC, USA
23. Medicare Payment Advisory Commission. Table 1-5-2 Update Framework for PPS Hospital Operating Payments, FY 1999. Report to Congress: Medicare Payment Policy, Volume I: Recommendations, March 1998, 57. Prospective Payment Assessment Commission, Washington DC, USA
24. MedPAC PPS Hospital Input Price Index (FY1992), Standard and Poors DRI HCC, 1st Qtr 1999
25. Federal Register, Vol. 63, No. 211, Nov. 2, 1998, 58814
26. American Medical Association. Current Procedural Terminology. Medicode Inc., 1999
27. Health Care Financing Administration, Medicare Part B Extraction and Surveillance System, 1998 (Data file)
28. Medicare Economic Index, Federal Register, Vol. 63, No. 211, Nov 2, 1998, 58891
29. Anesthesia Base Units obtained from Health Care Financing Administration, Jun 11, 1998
30. Anesthesia Time Units obtained from Federal Register, Vol. 59, No. 235, Dec 8, 1994
31. Iezzoni LI. Assessing quality using administrative data. Ann Intern Med 1997; 127: 666-74
32. Hlatky MA, Rogers WJ, Johnstone I, et al. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1997; 9: 92-99
33. Mushinski M. Average charges for coronary artery bypass grafts and percutaneous transluminal coronary angioplasties, 1995. Stat Bull Metropol Life Ins Co 1997; 78: 20
34. Lave JR, Pashos CL, Anderson GF, et al. Costing medical care: using Medicare administrative data. Med Care 1994; 32: JS77-89
35. Mitchell JB, Bubolz T, Paul JE, et al. Using Medicare claims for outcomes research. Med Care 1994; 32: JS38-51
36. Goff DC, Pandey DK, Chan FA, et al. Congestive heart failure in the United States. Is there more than meets the I(CD code)? The Corpus Christi Heart Project. Arch Intern Med 2000; 160: 197-202
37. Adhiyaman V, Kamalakannan D, Oke A, et al. Underutilization of antithrombotic therapy in atrial fibrillation. J R Soc Med 2000; 93 (3): 138-40
38. Bradford WD, Chen J, Krumholz HM. Under-utilisation of beta-blockers after acute myocardial infarction: pharmacoeconomic implications. Pharmacoeconomics 1999; 15 (3): 257-68
39. Davie AP. ACE inhibitors after myocardial infarction: clinical and economic considerations. Pharmacoeconomics 2000; 17 (3): 237-43
40. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999; 14: 711-7 [Accessed 2000 May 15]